Brief: Can Fite Pancreatic Carcinoma Phase IIa Study With Namodenoson Got Authorization From Israeli Ministry Of Health
16/09/2024 12:39
Sept 16 (Reuters) - Can Fite Biopharma Ltd CANF.TA :
* CAN FITE: PANCREATIC CARCINOMA PHASE IIA STUDY WITH
NAMODENOSON
GOT AUTHORIZATION FROM ISRAELI MINISTRY OF HEALTH
Source text for Eikon: ID:nGNX7h5FWV
Further company coverage: CANF.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Can Fite Biopharma
See all newsBrief: Corrected-Can Fite Biopharma Ltd Files For Offering Of Up To 6.6 mln Ordinary Shares By Selling Shareholders
Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study
Can-Fite BioPharma reports longer-than-anticipated overall survival in ongoing liver cancer study
Brief: Can Fite Biopharma Can-Fite Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
Can-Fite rises as skin drug study reaches interim analysis stage